James E. Peters

James E. Peters

Auto-generated profile, based on publicly available information

James E. Peters

Imperial College London

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2023 in Nature Immunology
Verified
Journal Article
Open access
PDF file
JZJing Hua Zhao
Jing Hua Zhao
DSDavid Stacey
David Stacey
NENiclas Eriksson
Niclas Eriksson
EMErin Macdonald-Dunlop
Erin Macdonald-Dunlop
ÅHÅsa K. Hedman
Åsa K. Hedman
JPJames E. Peters
James E. Peters
Circulating proteins have important functions in inflammation and a broad range of diseases. To identify genetic influences on inflammation-related proteins, we conducted a genome-wide protein quantitative trait locus (pQTL) study of 91 plasma proteins measured using the Olink Target platform in 14,824 participants. We identified 180 pQTLs (59 cis, 121 trans). Integration of pQTL data with eQTL and disease genome-wide association studies provided insight into pathogenesis, implicating lymphotoxin-α in multiple sclerosis. Using Mendelian randomization (MR) to assess causality in disease etiology, we identified both shared and distinct effects of specific proteins across immune-mediated diseases, including directionally discordant effects of CD40 on risk of rheumatoid arthritis versus multiple sclerosis and inflammatory bowel disease. MR implicated CXCL5 in the etiology of ulcerative colitis (UC) and we show elevated gut CXCL5 transcript expression in patients with UC. These results identify targets of existing drugs and provide a powerful resource to facilitate future drug target prioritization.

12 November 2019 in Nature Communications
Verified
Journal Article
Open access
PLPaul A Lyons
Paul A Lyons
JPJames E Peters
James E Peters
FAFederico Alberici
Federico Alberici
JLJames Liley
James Liley
RCRichard M. R. Coulson
Richard M. R. Coulson
KSKenneth G. C. Smith
Kenneth G. C. Smith
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare inflammatory disease of unknown cause. 30% of patients have anti-neutrophil cytoplasmic antibodies (ANCA) specific for myeloperoxidase (MPO). Here, we describe a genome-wide association study in 676 EGPA cases and 6809 controls, that identifies 4 EGPA-associated loci through conventional case-control analysis, and 4 additional associations through a conditional false discovery rate approach. Many variants are also associated with asthma and six are associated with eosinophil count in the general population. Through Mendelian randomisation, we show that a primary tendency to eosinophilia contributes to EGPA susceptibility. Stratification by ANCA reveals that EGPA comprises two genetically and clinically distinct syndromes. MPO+ ANCA EGPA is an eosinophilic autoimmune disease sharing certain clinical features and an HLA-DQ association with MPO+ ANCA-associated vasculitis, while ANCA-negative EGPA may instead have a mucosal/barrier dysfunction origin. Four candidate genes are targets of therapies in development, supporting their exploration in EGPA.

9 April 2021 in Nature Medicine
Verified
Journal Article
Open access
PDF file
LGLiam Gaziano
Liam Gaziano
CGClaudia Giambartolomei
Claudia Giambartolomei
APAlexandre C. Pereira
Alexandre C. Pereira
AGAnna Gaulton
Anna Gaulton
DPDaniel C. Posner
Daniel C. Posner
JCJuan P. Casas
Juan P. Casas
Drug repurposing provides a rapid approach to meet the urgent need for therapeutics to address COVID-19. To identify therapeutic targets relevant to COVID-19, we conducted Mendelian randomization analyses, deriving genetic instruments based on transcriptomic and proteomic data for 1,263 actionable proteins that are targeted by approved drugs or in clinical phase of drug development. Using summary statistics from the Host Genetics Initiative and the Million Veteran Program, we studied 7,554 patients hospitalized with COVID-19 and >1 million controls. We found significant Mendelian randomization results for three proteins (ACE2, P = 1.6 × 10−6; IFNAR2, P = 9.8 × 10−11 and IL-10RB, P = 2.3 × 10−14) using cis-expression quantitative trait loci genetic instruments that also had strong evidence for colocalization with COVID-19 hospitalization. To disentangle the shared expression quantitative trait loci signal for IL10RB and IFNAR2, we conducted phenome-wide association scans and pathway enrichment analysis, which suggested that IFNAR2 is more likely to play a role in COVID-19 hospitalization. Our findings prioritize trials of drugs targeting IFNAR2 and ACE2 for early management of COVID-19.

26 January 2022 in Immunity
Verified
Journal Article
Open access
BVBavithra Vijayakumar
Bavithra Vijayakumar
KBKarim Boustani
Karim Boustani
POPatricia P. Ogger
Patricia P. Ogger
APArtemis Papadaki
Artemis Papadaki
JTJames Tonkin
James Tonkin
JHJames A. Harker
James A. Harker
Some patients hospitalized with acute COVID-19 suffer respiratory symptoms that persist for many months. We delineated the immune-proteomic landscape in the airways and peripheral blood of healthy controls and post-COVID-19 patients 3 to 6 months after hospital discharge. Post-COVID-19 patients showed abnormal airway (but not plasma) proteomes, with an elevated concentration of proteins associated with apoptosis, tissue repair, and epithelial injury versus healthy individuals. Increased numbers of cytotoxic lymphocytes were observed in individuals with greater airway dysfunction, while increased B cell numbers and altered monocyte subsets were associated with more widespread lung abnormalities. A one-year follow-up of some post-COVID-19 patients indicated that these abnormalities resolved over time. In summary, COVID-19 causes a prolonged change to the airway immune landscape in those with persistent lung disease, with evidence of cell death and tissue repair linked to the ongoing activation of cytotoxic T cells.

29 March 2023 in Nature
Verified
Journal Article
Closed access
PDF file
YXYu Xu
Yu Xu
SRScott C. Ritchie
Scott C. Ritchie
YLYujian Liang
Yujian Liang
PTPaul Reimund Hugo Jan Timmers
Paul Reimund Hugo Jan Timmers
MPMaik Pietzner
Maik Pietzner
MIMichael Inouye
Michael Inouye

17 October 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
LCLingyan Chen
Lingyan Chen
JPJames E. Peters
James E. Peters
BPBram Peter Prins
Bram Peter Prins
EPElodie Persyn
Elodie Persyn
MTMatthew Traylor
Matthew Traylor
JHJoanna M. M. Howson
Joanna M. M. Howson
Stroke is the second leading cause of death with substantial unmet therapeutic needs. To identify potential stroke therapeutic targets, we estimate the causal effects of 308 plasma proteins on stroke outcomes in a two-sample Mendelian randomization framework and assess mediation effects by stroke risk factors. We find associations between genetically predicted plasma levels of six proteins and stroke (P ≤ 1.62 × 10−4). The genetic associations with stroke colocalize (Posterior Probability >0.7) with the genetic associations of four proteins (TFPI, TMPRSS5, CD6, CD40). Mendelian randomization supports atrial fibrillation, body mass index, smoking, blood pressure, white matter hyperintensities and type 2 diabetes as stroke risk factors (P ≤ 0.0071). Body mass index, white matter hyperintensity and atrial fibrillation appear to mediate the TFPI, IL6RA, TMPRSS5 associations with stroke. Furthermore, thirty-six proteins are associated with one or more of these risk factors using Mendelian randomization. Our results highlight causal pathways and potential therapeutic targets for stroke.